{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:10:03Z","timestamp":1792602603102,"version":"4.5.0"},"reference-count":56,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:p>Dupilumab, a monoclonal antibody against the common receptor of interleukin (IL)-4 and IL-13, was the first biologic therapy approved in Canada for treatment of moderate-to-severe atopic dermatitis (AD). While it is considered safe and effective, dupilumab is not universally effective and 8%-38% of patients develop conjunctivitis, while some patients develop head and neck dermatitis. Thus, new therapeutic options are warranted. While both IL-4 and IL-13 play important roles in the pathogenesis of AD, it has been recently demonstrated that IL-13 is the primary upregulated cytokine in AD skin biopsy samples. A placebo-controlled phase 2b clinical trial evaluating the efficacy and safety of lebrikizumab, an IL-13 inhibitor, in AD demonstrated that, at 16 weeks, Eczema Area and Severity Index (EASI) 75 and Investigator\u2019s Global Assessment (IGA) 0\/1 were achieved by 60.6% and 44.6% of patients taking lebrikizumab at its highest dose (vs 24.3% and 15.3% of patients taking placebo, respectively). Moreover, treatment with lebrikizumab was associated with rapid improvement of pruritus and low rates of conjunctivitis (1.4%-3.8%). Another IL-13 monoclonal antibody, tralokinumab, was evaluated for safety and efficacy in moderate-to-severe AD. By week 12, among adults receiving 300 mg tralokinumab, 42.5% achieved EASI-75 and 26.7% achieved IGA 0\/1 score (vs 15.5% and 11.8% in the placebo group, respectively). Both lebrikizumab and tralokinumab demonstrated acceptable safety profiles in AD (and non-AD) trials with adverse events often being comparable between treatment and control groups. Thus, IL-13 inhibitors may provide a safe and effective treatment alternative for patients with moderate-to-severe AD.<\/jats:p>","DOI":"10.1177\/1203475420982553","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T10:23:26Z","timestamp":1608632606000},"page":"315-328","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":31,"title":["Inhibition of IL-13: A New Pathway for Atopic Dermatitis"],"prefix":"10.1177","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1730-7178","authenticated-orcid":false,"given":"Kayadri","family":"Ratnarajah","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Universit\u00e9 Laval, Qu\u00e9bec, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Le","sequence":"additional","affiliation":[{"name":"Division of Dermatology, McGill University Health Centre, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9776-866X","authenticated-orcid":false,"given":"Anastasiya","family":"Muntyanu","sequence":"additional","affiliation":[{"name":"Division of Dermatology, McGill University Health Centre, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Mathieu","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Universit\u00e9 Laval, Qu\u00e9bec, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Nigen","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0562-4675","authenticated-orcid":false,"given":"Ivan V.","family":"Litvinov","sequence":"additional","affiliation":[{"name":"Division of Dermatology, McGill University Health Centre, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.","family":"Jack","sequence":"additional","affiliation":[{"name":"Division of Dermatology, McGill University Health Centre, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6692-7787","authenticated-orcid":false,"given":"Elena","family":"Netchiporouk","sequence":"additional","affiliation":[{"name":"Division of Dermatology, McGill University Health Centre, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,12,22]]},"reference":[{"key":"bibr1-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1177\/1203475416685077"},{"key":"bibr2-1203475420982553","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0138"},{"key":"bibr3-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13911"},{"key":"bibr4-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13120"},{"key":"bibr5-1203475420982553","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S211032"},{"key":"bibr6-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.12.022"},{"key":"bibr7-1203475420982553","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300300"},{"key":"bibr8-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1111\/all.13954"},{"key":"bibr9-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.12.018"},{"key":"bibr10-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.12.018"},{"key":"bibr11-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2020.01.005"},{"key":"bibr12-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0768-3"},{"key":"bibr13-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18163"},{"key":"bibr14-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0079"},{"key":"bibr15-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.2613"},{"key":"bibr16-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2017.08.010"},{"key":"bibr17-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.03.051"},{"key":"bibr18-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-206719"},{"key":"bibr19-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2017.12.006"},{"key":"bibr20-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.017"},{"key":"bibr21-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0079"},{"key":"bibr22-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12220"},{"key":"bibr23-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30265-X"},{"key":"bibr24-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03647.x"},{"key":"bibr25-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12725"},{"key":"bibr26-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.05.029"},{"key":"bibr27-1203475420982553","unstructured":"ClinicalTrials.gov. Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2) (ECZTRA 2). Accessed 27 June, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03160885?term=tralokinumab&cond=atopic+dermatitis&draw=1&rank=6"},{"key":"bibr28-1203475420982553","unstructured":"ClinicalTrials.gov. Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1) (ECZTRA 1). Accessed June 27, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03131648?term=tralokinumab&cond=atopic+dermatitis&draw=1&rank=7"},{"key":"bibr29-1203475420982553","doi-asserted-by":"crossref","unstructured":"Simpson E ea. Efficacy and safety of tralokinumab monotherapy in adult patients with moderate-to-severe atopic dermatitis: results from two 52-week Phase 3 trials (ECZTRA 1 and ECZTRA 2). American Academy of Dermatology Virtual Meeting Experience (AAD VMX); June 12, 2020.","DOI":"10.25251\/skin.4.supp.96"},{"key":"bibr30-1203475420982553","unstructured":"Tralokinumab Achieves Primary and Secondary Endpoints in Three Pivotal Phase 3 Trials in Adult Patients with Moderate-to-Severe Atopic Dermatitis. Accessed June 27, 2020. https:\/\/www.businesswire.com\/news\/home\/20200612005247\/en\/Tralokinumab-Achieves-Primary-Secondary-Endpoints-Pivotal-Phase"},{"key":"bibr31-1203475420982553","unstructured":"ClinicalTrials.gov. Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3). Accessed June 27, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03363854?term=tralokinumab&cond=atopic+dermatitis&draw=1&rank=4"},{"key":"bibr32-1203475420982553","doi-asserted-by":"crossref","unstructured":"Weidinger S ea. Efficacy and safety of tralokinumab with concomitant topical corticosteroid in adult patients with moderate-to-severe atopic dermatitis: Results from the 32-week Phase 3 ECZTRA 3 trial. American Academy of Dermatology Virtual Meeting Experience (AAD VMX); June 12, 2020.","DOI":"10.25251\/skin.4.supp.102"},{"key":"bibr33-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2017.12.001"},{"key":"bibr34-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00197-6"},{"key":"bibr35-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308004"},{"key":"bibr36-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30184-X"},{"key":"bibr37-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201704-0784OC"},{"key":"bibr38-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00223411"},{"key":"bibr39-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30201-7"},{"key":"bibr40-1203475420982553","first-page":"10","author":"Singh D.","year":"2010","journal-title":"BMC Pulm Med"},{"key":"bibr41-1203475420982553","first-page":"1","volume":"9","author":"Ferreira S.","year":"2020","journal-title":"Drugs Context"},{"key":"bibr42-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17869"},{"key":"bibr43-1203475420982553","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-019-00288-x"},{"key":"bibr44-1203475420982553","unstructured":"ClinicalTrials.gov. A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis. Accessed June 27, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02465606?term=lebrikizumab&cond=Atopic+Dermatitis&draw=2&rank=3"},{"key":"bibr45-1203475420982553","unstructured":"ClinicalTrials.gov. A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis. Accessed June 27, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02340234?term=lebrikizumab&cond=Atopic+Dermatitis&draw=2&rank=7"},{"key":"bibr46-1203475420982553","unstructured":"ClinicalTrials.gov. A Study of Lebrikizumab (LY3650150) in Patients With Moderate-to-Severe Atopic Dermatitis. Accessed June 27, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03443024?term=lebrikizumab&cond=Atopic+Dermatitis&draw=1&rank=4"},{"key":"bibr47-1203475420982553","unstructured":"ClinicalTrials.gov. Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate2). Accessed 27 June, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04178967?term=lebrikizumab&cond=Atopic+Dermatitis&draw=2&rank=5"},{"key":"bibr48-1203475420982553","unstructured":"ClinicalTrials.gov. Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1). Accessed June 27, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04146363?term=lebrikizumab&cond=Atopic+Dermatitis&draw=2&rank=6"},{"key":"bibr49-1203475420982553","unstructured":"ClinicalTrials.gov. Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate to Severe Atopic Dermatitis. (ADhere). Accessed June 27, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04250337?term=lebrikizumab&cond=Atopic+Dermatitis&draw=2&rank=8"},{"key":"bibr50-1203475420982553","unstructured":"ClinicalTrials.gov. Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (ADore). Accessed June 27, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04250350?term=lebrikizumab&cond=Atopic+Dermatitis&draw=2&rank=2"},{"key":"bibr51-1203475420982553","unstructured":"ClinicalTrials.gov. Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Patients With Moderate-to-Severe Atopic Dermatitis. Accessed June 27, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04392154?term=lebrikizumab&cond=Atopic+Dermatitis&draw=2&rank=1"},{"key":"bibr52-1203475420982553","unstructured":"ClinicalTrials.gov. Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4. Accessed June 27, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03556592?term=tralokinumab&cond=atopic+dermatitis&draw=1&rank=3"},{"key":"bibr53-1203475420982553","unstructured":"ClinicalTrials.gov. Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5) (ECZTRA 5). Accessed June 27, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03562377?term=tralokinumab&cond=atopic+dermatitis&draw=1&rank=5"},{"key":"bibr54-1203475420982553","unstructured":"ClinicalTrials.gov. Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6). Accessed June 27, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03526861?term=tralokinumab&cond=atopic+dermatitis&draw=1&rank=8"},{"key":"bibr55-1203475420982553","unstructured":"ClinicalTrials.gov. Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis Who Are Not Adequately Controlled With or Have Contraindications to Oral Cyclosporine A (ECZTRA 7). Accessed June 27, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03761537?term=tralokinumab&cond=atopic+dermatitis&draw=1&rank=2"},{"key":"bibr56-1203475420982553","unstructured":"ClinicalTrials.gov. Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND. Accessed June 27, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03587805?term=tralokinumab&cond=atopic+dermatitis&draw=1&rank=1"}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1203475420982553","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1203475420982553","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1203475420982553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:54:47Z","timestamp":1777391687000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1203475420982553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,22]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1177\/1203475420982553"],"URL":"https:\/\/doi.org\/10.1177\/1203475420982553","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"value":"1203-4754","type":"print"},{"value":"1615-7109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,22]]}}}